Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-19T16:55:41.593Z Has data issue: false hasContentIssue false
  • English
  • Français

RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance

Published online by Cambridge University Press:  21 May 2009

Alvin J.X. Lee ,
Richard Kolesnick  and
Charles Swanton
Alvin J.X. Lee
Affiliation:
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK.
Richard Kolesnick
Affiliation:
Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Charles Swanton*
Affiliation:
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK. Royal Marsden NHS Foundation Trust, Breast and Drug Development Units, Downs Road, Sutton, UK.
*
*Corresponding author: Charles Swanton, Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London, WC2A 3PX, UK. Tel: +44 20 7269 3463; Fax: +44 20 7269 3094; E-mail: charles.swanton@cancer.org.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Acquired drug resistance limits the efficacy of cytotoxics used in the management of haematological and solid tumours and is responsible for the declining clinical benefit following successive treatment regimens in metastatic cancers. Treatment failure has a major impact on quality of life and survival in advanced disease. Defining pathways of intrinsic and acquired drug resistance may provide new targets to prolong drug efficacy and time to disease progression. Predicting the intrinsic drug sensitivity of human tumours in advance of cytotoxic therapy is of paramount importance in order to limit unnecessary toxicity and optimise treatment outcome. RNA interference (RNAi) provides a powerful tool to annotate gene function and systematically define drug-resistance pathways. High-throughput screening RNAi technology has provided evidence for drug-specific resistance pathways as well as novel pathways implicated in multidrug sensitivity. The challenge is how to integrate these data with biological samples to define relevant drug-resistant pathways in vivo.

Type
Review Article
Information
Expert Reviews in Molecular Medicine , Volume 11 , July 2009 , e15
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

1Longley, D.B. and Johnston, P.G. (2005) Molecular mechanisms of drug resistance. Journal of Pathology 205, 275-292Google Scholar
2Szakacs, G. et al. (2006) Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 5, 219-234CrossRefGoogle ScholarPubMed
3Downward, J. (2004) Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene 23, 8376-8383Google Scholar
4Swanton, C. et al. (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512CrossRefGoogle ScholarPubMed
5Sudo, T. et al. (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Research 64, 2502-2508CrossRefGoogle ScholarPubMed
6Roschke, A.V. et al. (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Research 63, 8634-8647Google Scholar
7Cahill, D.P. et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300-303Google Scholar
8Shin, H.J. et al. (2003) Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 4, 483-497CrossRefGoogle ScholarPubMed
9Vogel, C. et al. (2004) Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23, 6845-6853Google Scholar
10Roberts, J.R. et al. (1990) Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Research 50, 710-716Google ScholarPubMed
11Kops, G.J., Foltz, D.R. and Cleveland, D.W. (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proceedings of the National Academy of Sciences of the United States of America 101, 8699-8704Google Scholar
12Potti, A. et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nature Medicine 12, 1294-1300Google Scholar
13Carter, S.L. et al. (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genetics 38, 1043-1048Google Scholar
14 [Deleted at proof stage]Google Scholar
15Swanton, C. et al. CINATRA: Chromosomal instability and anti-tubulin response assessment. A phase II clinical trial of EPO-906 in metastatic colorectal cancer. http://science.cancerresearchuk.org/reps/pdfs/cinatra_trial_synopsis.pdfGoogle Scholar
16Swanton, C., Tomlinson, I. and Downward, J. (2006) Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5, 818-823Google Scholar
17Whitehurst, A. et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819Google Scholar
18Hernandez-Vargas, H. et al. (2007) Inhibition of paclitaxel-induced proteasome activation influences paclitaxel cytotoxicity in breast cancer cells in a sequence-dependent manner. Cell Cycle 6, 2662-2668Google Scholar
19Rouzier, R. et al. (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 102, 8315-8320Google Scholar
20Pustzai, L. et al. (2008) Evaluation of microtubule associated protein Tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Presented at the CTRC-AACR San Antonio Breast Cancer Symposium (10–14 December 2008; San Antonio, TX, USA), http://www.abstracts2view.com/sabcs/view.php?nu_SABCS08L_505Google Scholar
21Broker, L.E. et al. (2004) Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Research 64, 27-30Google Scholar
22Groth-Pedersen, L. et al. (2007) Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Research 67, 2217-2225Google Scholar
23Bartz, S.R. et al. (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Molecular and Cellular Biology 26, 9377-9386CrossRefGoogle ScholarPubMed
24D'Andrea, A.D. (2003) The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2, 290-292Google ScholarPubMed
25van Haaften, G. et al. (2006) Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi. Current Biology 16, 1344-1350Google Scholar
26Baldwin, R.M. et al. (2006) Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene 25, 2909-2919CrossRefGoogle ScholarPubMed
27Giroux, V., Iovanna, J. and Dagorn, J.C. (2006) Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. The FASEB Journal 20, 1982-1991Google Scholar
28Swanton, C. et al. (2007) Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. Cell Cycle 6, 2001-2004CrossRefGoogle ScholarPubMed
29Wey, J.S. et al. (2005) Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. British Journal of Cancer 93, 233-241CrossRefGoogle ScholarPubMed
30Gana-Weisz, M. et al. (2002) The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clinical Cancer Research 8, 555-565Google ScholarPubMed
31Berns, K. et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402Google Scholar
32Nagata, Y. et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127Google Scholar
33Morgan-Lappe, S. et al. (2006) RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25, 1340-1348CrossRefGoogle ScholarPubMed
34Turner, N.C. et al. (2008) A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO Journal 27, 1368-1377Google Scholar
35Hattori, H. et al. (2007) RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 110, 640-650Google Scholar
36Nobili, S. et al. (2006) Pharmacological strategies for overcoming multidrug resistance. Current Drug Targets 7, 861-879Google Scholar
37Hanada, K. et al. (2003) Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803-809CrossRefGoogle ScholarPubMed
38Obeid, L.M. et al. (1993) Programmed cell death induced by ceramide. Science 259, 1769-1771Google Scholar
39Pettus, B.J., Chalfant, C.E. and Hannun, Y.A. (2002) Ceramide in apoptosis: an overview and current perspectives. Biochimica et Biophysica Acta 1585, 114-125Google Scholar
40Gouaze, V. et al. (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Research 65, 3861-3867Google Scholar
41Itoh, M. et al. (2003) Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clinical Cancer Research 9, 415-423Google ScholarPubMed
42Liu, Y.Y. et al. (2008) A role for ceramide in driving cancer cell resistance to doxorubicin. The FASEB Journal 22, 2541-2551CrossRefGoogle ScholarPubMed
43Dawson, K. et al. (2008) Loss of regulators of vacuolar ATPase function and ceramide synthesis results in multidrug sensitivity in Schizosaccharomyces pombe. Eukaryotic Cell 7, 926-937Google Scholar
44Liu, X. et al. (2008) Acid ceramidase inhibition: a novel target for cancer therapy. Frontiers in Bioscience 13, 2293-2298Google Scholar
45Min, J. et al. (2007) (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Molecular Cancer Research 5, 801-812Google Scholar
46Kolesnick, R. (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. Journal of Clinical Investigation 110, 3-8Google Scholar
47Reynolds, C.P., Maurer, B.J. and Kolesnick, R.N. (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Letters 206, 169-180Google Scholar
48Borst, P. et al. (2000) A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 92, 1295-1302Google Scholar
49Glasspool, R.M., Teodoridis, J.M. and Brown, R. (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. British Journal of Cancer 94, 1087-1092Google Scholar
50Duesberg, P., Stindl, R. and Hehlmann, R. (2001) Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proceedings of the National Academy of Sciences of the United States of America 98, 11283-11288CrossRefGoogle ScholarPubMed
51Duesberg, P., Stindl, R. and Hehlmann, R. (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalysed by aneuploidy. Proceedings of the National Academy of Sciences of the United States of America 97, 14295-14300Google Scholar

Further reading, resources and contacts

Online bioinformatics software for pathway analysis:

Downward, J. (2004) Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene 23, 8376-8383Google Scholar
Bartz, S. and Jackson, A.L. (2005) How will RNAi facilitate drug development? Sci STKE 2005, pe39Google Scholar
http://www.genego.com/Google Scholar
Downward, J. (2004) Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene 23, 8376-8383Google Scholar
Bartz, S. and Jackson, A.L. (2005) How will RNAi facilitate drug development? Sci STKE 2005, pe39Google Scholar
http://www.genego.com/Google Scholar